{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T05:17:27Z","timestamp":1740460647817,"version":"3.37.3"},"reference-count":29,"publisher":"European Respiratory Society (ERS)","issue":"5","content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2018,5,1]]},"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1183\/13993003.00817-2018","type":"journal-article","created":{"date-parts":[[2018,5,24]],"date-time":"2018-05-24T08:00:13Z","timestamp":1527148813000},"page":"1800817","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Aminopeptidase antibodies in mesothelioma: new wine deserves new sacks"],"prefix":"10.1183","volume":"51","author":[{"given":"Jan P.","family":"van Meerbeeck","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerrit","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Giovannetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Godefridus J.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"81","published-online":{"date-parts":[[2018,5,24]]},"reference":[{"key":"2024101909443398000_51.5.1800817.1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01610-2017"},{"key":"2024101909443398000_51.5.1800817.2","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s00726-013-1648-0","article-title":"Positioning of aminopeptidase inhibitors in next generation cancer therapy","volume":"46","author":"Hitzerd","year":"2014","journal-title":"Amino Acids"},{"key":"2024101909443398000_51.5.1800817.3","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"44","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"2024101909443398000_51.5.1800817.4","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9896(199706)182:2<211::AID-PATH834>3.0.CO;2-D"},{"key":"2024101909443398000_51.5.1800817.5","first-page":"795","article-title":"Human aminopeptidases: a review of the literature","volume":"26","author":"Sanderink","year":"1988","journal-title":"J Clin Chem Clin Biochem"},{"key":"2024101909443398000_51.5.1800817.6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2010.01826.x"},{"key":"2024101909443398000_51.5.1800817.7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-002931"},{"key":"2024101909443398000_51.5.1800817.8","doi-asserted-by":"publisher","DOI":"10.2174\/1389200013338748"},{"key":"2024101909443398000_51.5.1800817.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2008.06.003"},{"key":"2024101909443398000_51.5.1800817.10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.6295"},{"key":"2024101909443398000_51.5.1800817.11","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-6627"},{"key":"2024101909443398000_51.5.1800817.12","doi-asserted-by":"crossref","first-page":"352","DOI":"10.5306\/wjco.v7.i5.352","article-title":"Role of Akt signaling in resistance to DNA-targeted therapy","volume":"7","author":"Avan","year":"2016","journal-title":"World J Clin Oncol"},{"key":"2024101909443398000_51.5.1800817.13","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1093\/annonc\/mdx499","article-title":"Role of proton-coupled folate transporter in pemetrexed-resistance of mesothelioma:clinical evidence and new pharmacological tools","volume":"28","author":"Giovannetti","year":"2017","journal-title":"Ann Oncol"},{"key":"2024101909443398000_51.5.1800817.14","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.400"},{"key":"2024101909443398000_51.5.1800817.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01238-6"},{"key":"2024101909443398000_51.5.1800817.16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.41.5869"},{"key":"2024101909443398000_51.5.1800817.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061884"},{"key":"2024101909443398000_51.5.1800817.18","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq020"},{"key":"2024101909443398000_51.5.1800817.19","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.368"},{"key":"2024101909443398000_51.5.1800817.20","unstructured":"National Comprehensive Cancer Network. NCCN guidelines. www.nccn.org\/professionals\/physician_gls\/pdf\/mpm.pdf Date last accessed: April 2, 2018."},{"key":"2024101909443398000_51.5.1800817.21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2017.05.012","article-title":"Cost-effectiveness analysis of additional bevacizumab to pemetrexed plus cisplatin for malignant pleural mesothelioma based on the MAPS trial","volume":"110","author":"Zhan","year":"2017","journal-title":"Lung Cancer"},{"key":"2024101909443398000_51.5.1800817.22","unstructured":"Laszlo V , Ozsar J , Klikovits T , et al. Preclinical investigation of the therapeutic potential of nintedanib in malignant pleural mesothelioma. Proceedings of the 13th International Conference of the International Mesothelioma Interest Group 2016; Abstract PP02.61."},{"key":"2024101909443398000_51.5.1800817.23","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1200\/JCO.2017.72.9012","article-title":"Nintedanib plus pemetrexed\/cisplatin in patients with malignant pleural mesothelioma: phase II results from the randomized, placebo-controlled LUME-Meso trial","volume":"35","author":"Grosso","year":"2017","journal-title":"J Clin Oncol"},{"key":"2024101909443398000_51.5.1800817.24","unstructured":"Boehringer Ingelheim. LUME-Meso: double blind, randomised, multicentre, phase II\/III study of nintedanib in combination with pemetrexed\/cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemetrexed\/cisplatin followed by continuing placebo monotherapy for the treatment of patients with unresectable malignant pleural mesothelioma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01907100 Date last updated: March 13, 2018. Date last accessed: April 28, 2018."},{"key":"2024101909443398000_51.5.1800817.25","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv249"},{"key":"2024101909443398000_51.5.1800817.26","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00063109"},{"key":"2024101909443398000_51.5.1800817.27","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv199"},{"key":"2024101909443398000_51.5.1800817.28","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2017-211321"},{"key":"2024101909443398000_51.5.1800817.29","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1200\/JCO.2017.76.6394","article-title":"Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Kindler","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.00817-2018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T06:57:50Z","timestamp":1740380270000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.00817-2018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":29,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2018,5,24]]},"published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1183\/13993003.00817-2018"],"URL":"https:\/\/doi.org\/10.1183\/13993003.00817-2018","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"type":"print","value":"0903-1936"},{"type":"electronic","value":"1399-3003"}],"subject":[],"published":{"date-parts":[[2018,5]]}}}